New York City will permanently pay drug users to return used needles, up to $10 a day, after Mayor Zohran Mamdani’s administration quietly locked the Community Syringe Redemption Program into the city’s new budget. The $3 million line item, tucked inside a $126 billion spending plan, converts what began as a pilot into a fixture of city government, Fox News reported.
The program pays 20 cents per used syringe. Participants can bring back up to 50 needles a day at eight designated drop-off sites across the city, five in the Bronx, one each in Brooklyn, Manhattan, and Queens. The money comes from more than $189 million in opioid settlement funds the city secured from major drug manufacturers and distributors.
That detail is where the controversy sharpens. Those settlement dollars were extracted from the companies that fueled the opioid crisis, money meant to help communities recover from addiction. Instead, New York City is routing a portion of it directly into the hands of active drug users, with no requirement that they seek treatment.
One participant made the arrangement plain. Tamia Wright, 43, who returned needles at a Bronx park, told the New York Post exactly what she planned to do with the cash:
“It’s definitely a side hustle for me. Yeah, definitely! Right now, I’m gonna buy some weed with [the earnings] and cigarettes.”
Wright’s candor captures the core problem critics have identified since the program launched in March 2025. The city is not paying people to get clean. It is paying people to bring back used needles, and what they do with the money afterward is their business.
During its first year, the program paid out approximately $292,000 to more than 1,700 participants. Over roughly 16 months of operation, it has collected more than 2.3 million used syringes. A nonprofit called Addiction Response Resources runs the day-to-day operation under an $11.1 million city contract that extends through the end of next year.
The same organization operates a similar syringe redemption program in Boston.
Budget documents submitted to the New York City Council on June 30 included the $3 million allocation. Newsmax reported that the program was folded into the spending plan without floor debate, a maneuver that allowed it to become permanent without the kind of public airing a standalone vote would have demanded. The Council subsequently approved the budget.
The legislative groundwork was laid in 2022, when progressive City Council members passed legislation authorizing the program. It took until March 2025 for the pilot to launch. Now, barely 16 months later, the Mamdani administration has made it a permanent budget item.
New York City’s spending habits are no stranger to controversy. The same political class that approved this program has presided over transit payroll costs that dwarf what most taxpayers earn, and a regulatory environment that grows more expensive by the year.
Queens Republican Councilwoman Joann Ariola offered the sharpest objection. She argued the opioid settlement funds being used to bankroll the program have a more obvious purpose:
“All this is doing is putting money in the pockets of addicts, so they can continue to fuel their habits, rather than helping them break free of their disease.”
Ariola said the settlement cash “should all be going toward addiction treatment services, not for paying users to turn in their needles for cash.”
The criticism was not limited to Republicans. Bronx Democratic Councilman Oswald Feliz credited the effort to remove discarded syringes from neighborhoods but warned that the city “should not recklessly create conditions that can threaten the safety of vulnerable communities.” That warning, from a Democrat representing one of the boroughs most saturated with redemption sites, suggests the unease crosses party lines.
New York’s progressive leadership has a pattern of prioritizing ideological programs over practical results. The same state legislature recently advanced legislation rewriting basic family terminology in state law, signaling where the political energy flows in Albany and City Hall.
Health Department spokesperson Rachel Vick defended the program, saying it helps residents “live in a community free of syringe litter” while safely disposing of medical waste and connecting people in need with nearby care.
City officials point to Sanitation Department data showing a decline in discarded needles. Workers have collected 26,229 needles so far this year, compared with 64,560 during the same period in 2025, a drop of roughly 59 percent. Supporters credit the redemption program with driving that improvement.
But the Health Department’s framing sidesteps the harder question. The program is not designed to reduce drug use. It does not require participants to enter treatment, attend counseling, or take any step toward recovery. It treats syringe litter as the problem and cash payments as the solution, while the addiction itself continues unchecked.
The Health Department urges residents to safely dispose of sharps or report syringe litter through 311. That is sensible public health messaging. Paying active users cash for their used needles is something else entirely.
The funding source matters. Opioid settlement funds represent the legal system’s attempt to hold pharmaceutical companies accountable for the devastation their products caused. Cities and states fought for years to secure those dollars. New York City received more than $189 million.
The intended purpose of that money, treatment, recovery infrastructure, prevention, is not ambiguous. Ariola’s argument that it “should all be going toward addiction treatment services” is not a fringe position. It is the commonsense reading of why the money exists.
Instead, New York City is spending a portion of it on a program where a participant openly describes the payments as a “side hustle” and plans to spend the earnings on marijuana and cigarettes. The city does not appear to track whether participants use the cash for drugs, food, or anything else. The only metric that matters, by the program’s own design, is the number of syringes collected.
Meanwhile, the broader question of public safety in New York City remains acute. The same city government that funds needle buybacks has faced ongoing challenges with federal judges limiting immigration enforcement in its courthouses and persistent disorder on its streets and transit system.
Cash-for-syringes programs carry an incentive problem that their advocates rarely address head-on. If the city pays for returned needles, it creates a financial motive to acquire more needles. The program caps redemptions at 50 syringes per day, but that cap itself reveals the scale of use the city expects from individual participants.
Five of the eight redemption sites sit in the Bronx, a borough already bearing a disproportionate share of the city’s addiction crisis. Councilman Feliz’s warning about “recklessly creating conditions” that threaten vulnerable communities reflects a legitimate concern: concentrating cash-for-needle exchanges in already struggling neighborhoods may attract more of the activity those neighborhoods are trying to escape.
The program’s defenders argue that collecting 2.3 million syringes off the streets is a public health win. That number is real. But it also quantifies the sheer volume of intravenous drug use the city is managing around, not reducing.
Across the country, communities grapple with how to handle the consequences of addiction without enabling it. New York City has chosen a path that prioritizes litter reduction over recovery, cash incentives over treatment, and quiet budget maneuvers over public debate. The flow of illegal drugs into the country continues to fuel demand, and cities like New York are left managing the downstream wreckage.
Mayor Mamdani’s decision to make the Community Syringe Redemption Program permanent tells you where his administration’s priorities sit. The city will spend $3 million a year, drawn from funds meant to fight addiction, to pay drug users for their used needles, with no treatment requirement, no recovery benchmarks, and no accountability for how the cash gets spent.
The pilot phase, by definition, was supposed to be temporary. It was supposed to prove the concept worked before the city committed long-term resources. What the pilot actually proved is that if you pay people cash for needles, they will bring you needles. Whether it proved anything about reducing addiction, improving public health outcomes, or making neighborhoods safer is a question the Mamdani administration apparently decided it did not need to answer before writing the check.
Opioid settlement money was fought for in courtrooms across the country because addiction destroyed families and communities. Turning that money into a needle buyback program, one that a participant cheerfully calls a “side hustle”, is not harm reduction. It is a city government that has confused managing a crisis with solving one.
By signing up, you agree to receive newsletters and promotional content from American Frontline News and selected publications in the American Digest Media Network, operated with Patriot Mom Digest LLC, and you accept our Terms of Use and Privacy Policy. You may unsubscribe at any time.
By signing up, you agree to receive newsletters and promotional content from American Frontline News and selected publications in the American Digest Media Network, operated with Patriot Mom Digest LLC, and you accept our Terms of Use and Privacy Policy. You may unsubscribe at any time.